International Journal of Clinical Case Reports 2024, Vol.14, No.5, 230-241 http://medscipublisher.com/index.php/ijccr 240 Lopes A., Vandermeulen G., and Préat V., 2019, Cancer DNA vaccines: current preclinical and clinical developments and future perspectives, Journal of Experimental and Clinical Cancer Research : CR, 38(1): 146. https://doi.org/10.1186/s13046-019-1154-7 PMID: 30953535 PMCID: PMC6449928 Lai X., and Friedman A., 2017, Combination therapy of cancer with cancer vaccine and immune checkpoint inhibitors: a mathematical model, PLoS ONE, 12(5): e0178479. https://doi.org/10.1371/journal.pone.0178479 PMID: 28542574 PMCID: PMC5444846 Liao J., and Zhang S., 2021, Safety and efficacy of personalized cancer vaccines in combination with immune checkpoint inhibitors in cancer treatment, Frontiers in Oncology, 11: 663264. https://doi.org/10.3389/fonc.2021.663264 PMID: 34123821 PMCID: PMC8193725 Massarelli E., William W., Johnson F., Kies M., Ferrarotto R., Guo M., Feng L., Lee J., Tran H., Kim Y., Haymaker C., Bernatchez C., Curran M., Barrese T., Canales J., Wistuba I., Li L., Wang J., Burg S., Melief C., and Glisson B., 2019, Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16-related cancer: a phase 2 Clinical Trial, JAMA Oncology, 5: 67-73. https://doi.org/10.1001/jamaoncol.2018.4051 PMID: 30267032 PMCID: PMC6439768 Murahashi M., Hijikata Y., Yamada K., Tanaka Y., Kishimoto J., Inoue H., Marumoto T., Takahashi A., Okazaki T., Takeda K., Hirakawa M., Fujii H., Okano S., Morita M., Baba E., Mizumoto K., Maehara Y., Tanaka M., Akashi K., Nakanishi Y., Yoshida K., Tsunoda T., Tamura K., Nakamura Y., and Tani K., 2016, Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors., Clinical Iimmunology, 166-167: 48-58. https://doi.org/10.1016/j.clim.2016.03.015 Morse M., Gwin W., and Mitchell D., 2021, Vaccine therapies for cancer: then and now, Targeted Oncology, 16: 121-152. https://doi.org/10.1007/s11523-020-00788-w PMID: 33512679 PMCID: PMC7845582 Ogi C., and Aruga A., 2015, Approaches to improve development methods for therapeutic cancer vaccines., Immunology Letters, 164(2): 100-108. https://doi.org/10.1016/j.imlet.2015.02.010 Peres L., Luz F., Pultz B., Brígido P., Araújo R., Goulart L., and Silva M., 2015, Peptide vaccines in breast cancer: the immunological basis for clinical response., Biotechnology Advances, 33(8): 1868-1877. https://doi.org/10.1016/j.biotechadv.2015.10.013 Pilla L., Ferrone S., and Maccalli C., 2018, Methods for improving the immunogenicity and efficacy of cancer vaccines, Expert Opinion on Biological Therapy, 18: 765-784. https://doi.org/10.1080/14712598.2018.1485649 PMID: 29874943 PMCID: PMC8670419 Rahman M., Behl T., Islam M., Alam M., Islam M., Albarrati A., Albratty M., Meraya A., and Bungău S., 2022, Emerging management approach for the adverse events of immunotherapy of cancer, Molecules, 27(12): 3798. https://doi.org/10.3390/molecules27123798 PMID: 35744922 PMCID: PMC9227460 Ramos-Casals M., Brahmer J., Callahan M., Flores-Chávez A., Keegan N., Khamashta M., Lambotte O., Mariette X., Prat A., and Suarez-Almazor M., 2020, Immune-related adverse events of checkpoint inhibitors, Nature Reviews Disease Primers, 6(1): 38. https://doi.org/10.1038/s41572-020-0160-6 PMID: 32382051 PMCID: PMC9728094 Spagnolo F., Boutros A., Croce E., Cecchi F., Arecco L., Tanda E., Pronzato P., and Lambertini M., 2021, Influenza vaccination in cancer patients receiving immune checkpoint inhibitors: a systematic review, European Journal of Clinical Investigation, 51(7): e13604. https://doi.org/10.1111/eci.13604 PMID: 34021591 PMCID: PMC8365730 Suekane S., Yutani S., Toh U., Yoshiyama K., and Itoh K., 2022, Immune responses of patients without cancer recurrence after a cancer vaccine over a long term, Molecular and Clinical Oncology, 16(6): 112. https://doi.org/10.3892/mco.2022.2545 PMID: 35620212 PMCID: PMC9112399 Schneider K., Grønhøj C., Hahn C., and Buchwald C., 2018, Therapeutic human papillomavirus vaccines in head and neck cancer: a systematic review of current clinical trials, Vaccine, 36(45): 6594-6605. https://doi.org/10.1016/j.vaccine.2018.09.027 PMID: 30268734 Soltani M., Savvateeva L., Ganjalikhani-Hakemi M., and Jr A., 2022, Clinical combinatorial treatments based on cancer vaccines: combination with checkpoint inhibitors and beyond, Current Drug Targets, 23(11): 1072-1084. https://doi.org/10.2174/1389450123666220421124542 PMID: 35593358
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==